Small Pharma

Cybin Chief Business Officer @GeorgeTziras will participate in a fireside chat at the @GuggenheimPtnrs 2nd Annual Healthcare Innovation Conference at 4:30 pm ET on November 10, 2025. Click here to join the webcast: shorturl.at/W4fyy

Cybin is pleased to announce a ~$175 million registered direct offering with prominent biotech investors. Learn more: ir.cybin.com/investors/news…

We’re pleased to share that Cybin’s Chief Medical Officer, @dramirinamdar and Chief Business Officer, @GeorgeTziras, will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Wednesday, September 17, 2025, at 9:20 a.m. ET. Learn more: ir.cybin.com/investors/news/

We're excited to share that Cybin’s Senior Vice President of Clinical Operations, Allison House-Gecewicz, will join industry leaders at the 8th Annual Neuropsychiatric Drug Development Summit to share insights during the seminar “Revitalizing Psychedelic Clinical Trials: Harnessing Lessons Learned to Drive Operational Excellence & Regulatory Alignment.” Learn more: neuropsychiatric-drug-development.com/seminar/revita…

“Completing enrollment in our Phase 2 study of CYB004 marks a significant milestone on our path to bringing forth an effective treatment for Generalized Anxiety Disorder (GAD),” said @EricSo168168, Interim Chief Executive Officer of Cybin. CYB004 is a short duration treatment with convenient intramuscular dosing, offering new hope for hundreds of millions of people affected by GAD and anxiety disorders worldwide. Learn more: ir.cybin.com/investors/news/ @dramirinamdar @GlavinePaul @GeorgeTziras

Cybin’s Chief Business Officer, @GeorgeTziras, will participate in a fireside chat at the @HCWCO 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:00 a.m. ET. Click here to access the webcast: ir.cybin.com/investors/even…

Join Cybin's Chief Medical Officer, @dramirinamdar for a fireside chat at the Cantor Global Healthcare Conference this Friday, Sept. 5, at 10:20 am ET.    Register for the webcast here: loom.ly/Ec3TuPg

AbbVie (NYSE: $ABBV) is going all in on Gilgamesh’s lead depression drug bretisilocin (GM-2505) with an acquisition deal valued up to $1.2B, following strong Phase 2a results. 🔹 Transaction builds on 2024 collaboration & licensing option agreement 🔹 Bretisilocin showed rapid, durable efficacy in MDD with up to 94% remission at 4 weeks 🔹 AbbVie's move signals high conviction in Bretisilocin's potential as a novel treatment for MDD 🔹 Bretisilocin and @CybinInc's CYB003 deliver standout efficacy and durability results in depression from Phase 2 studies 🔹 AbbVie acquisition establishes key value benchmark for those perceived to be the most promising novel candidates in MDD Follow along with Robert Sassoon at our website below! watertowerresearch.com/doc?docID=UR_C… $CYBN #Cybin #CYB003 #MDD #SmallCap #Stocks #Investing #Depression #WTRInsights

#ICYMI: Last week, Cybin CEO @insidepharma was featured in a fireside chat hosted by Jim Molloy at Alliance Global Partners (A.G.P.)'s Virtual Healthcare Showcase. Tune in to the replay to learn more about Cybin's progress with its lead clinical-stage programs CYB003 and CYB004, and the ongoing Phase 3 PARADIGM program evaluating CYB003 in major depressive disorder. Watch the replay here: vimeo.com/1086093303/90c…

@CybinInc was honored to participate in the 28th Annual @MilkenInstitute Global Conference on May 5th, 2025, where CEO @insidepharma discussed the role of innovation in realizing new standards of care for the treatment of mental health as part of a panel discussion on the Global Landscape and Opportunities for Medical Breakthroughs. Watch the webcast: vimeo.com/1076350224 #MIGlobal #BreakthroughTherapy #MentalHealthInnovation

May is #MentalHealthAwarenessMonth, and at #Cybin, we're pioneering new paths in mental healthcare for the benefit of patients worldwide. Too many are suffering in silence. This month, we rededicate ourselves to raising awareness and realizing new treatment options. Together, we can change minds.

“It’s truly an honor to return to the @MilkenInstitute Conference and to contribute to the discourse around the opportunities we have as drug developers today,” said #Cybin CEO @insidepharma  Learn more: loom.ly/4r6Nng0 #MIGlobal

“This strategic partnership agreement model serves to take advantage of the deep expertise of each individual site and ensure that protocols and best practices are shared consistently,” said #Cybin CEO @insidepharma Learn more: ir.cybin.com/investors/news/

“Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with @OsmindHQ will help us accelerate our goals,” said #Cybin CEO @insidepharma. "Osmind’s extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments such as #CYB003 and #CYB004." Learn more: ir.cybin.com/investors/news/

"What we’re seeing with our treatment is, after just two doses, and I don’t mean two doses a week or two doses a month, I mean just two doses, we see 75% of patients in remission from their depression and 71% still in remission one year later." Read #Cybin CEO @insidepharma's full interview: loom.ly/8zgFW0s @InvezzPortal

Rapid and durable effects have been observed in #DMT studies, with: ✓ Improvements in anxiety and well-being scores ✓ Safe and well-tolerated intramuscular route ✓ Safe and well-tolerated when co-administered with SSRIs Learn more: loom.ly/WEGP3es

#GAD is characterized by persistent and excessive worry about health, work, social interactions, and everyday routines. Symptoms include restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. Learn more: loom.ly/WEGP3es

There are just 4 US-approved medicines for Generalized Anxiety Disorder — all SSRIs & SNRIs. With no new approval in 15+ years, they provide only limited relief to many sufferers. In recent market research commissioned by Cybin, we learned from psychiatrists that the majority of their #GAD patients are treatment resistant to available medicines and are desperate for new alternatives. (1) CYB004 Phase 2 topline data is expected 1H2025. Learn more at cybin.com/cyb004.

CYB004 is #Cybin’s proprietary, deuterated DMT molecule in a Phase 2 study for Generalized Anxiety Disorder (#GAD) — potentially offering a short-duration treatment to disrupt negative thought patterns and transform the care of people with GAD. Learn more: cybin.com/cyb004

Nearly 70% of #MDD patients take antidepressants. #Cybin is developing #CYB003 as an acute, adjunctive therapy—potentially enabling immediate treatment without patients waiting to withdraw and eliminating logistical hurdles. Learn more: loom.ly/SRZ80Bk